BrainStorm Cell Therapeutics, Inc. (BCLI) Gets European Orphan Drug Designation for NurOwn Treatment
BrainStorm Cell Therapeutics is a leading biotechnology developer of adult stem cell therapies, derived from autologous bone narrow cells, for neurodegenerative diseases. The company holds the rights to develop and commercialize its own NurOwn technology through an exclusive, global licensing agreement with Ramot, the technology transfer company of Tel Aviv University. The company reported today that the European Commission has granted 'orphan drug' status for NurOwn. This is BrainStorm's adult stem cell therapy, consisting of bone marrow-derived mesenchymal stromal cells secreting neurotrophic factors, for treatment of Amyotrophic Lateral Sclerosis (ALS), which is also known as Lou Gehrig's Disease. The company…